Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
about
Tramadol extended-release in the management of chronic painThe David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environmentUse of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran communityLumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.Celecoxib and cardiovascular risks.COX-2 inhibitors and the heart: are all coxibs the same?Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.COX-2 inhibition: a possible role in the management of prostate cancer?Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins.Review of the cardiovascular safety of COXIBs compared to NSAIDS.Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?Myths and facts in the use of anti-inflammatory drugs.Celecoxib in arthritis: relative risk management profile and implications for patients.Recent advances in the pharmaceutical management of pain.Celecoxib for the treatment of atherosclerosis.Rationales and choices for the treatment of patients with NYHA class II heart failure.The cardiovascular safety of celecoxib.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.COX 2 inhibitors, traditional NSAIDs, and the heart.Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study.Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.Possible arrhythmiogenic mechanism produced by ibuprofen.Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.Prevalence of in-hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure.Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network based on the Hospital to Home (H2H) InAngiotensin-converting enzyme inhibitors and survival in women and men with heart failureSex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - A population study
P2860
Q24654636-6A85D181-CAE9-47B4-9F11-756381D67B35Q28222253-9F4D3BD7-5FBF-4AAC-8F0D-0E24D003A41EQ33906348-287F4646-CC75-4659-8C4E-C0F1EDDC51AEQ34449825-6D800B9C-DCA8-4CB0-9B04-A4885F5F22A4Q34474985-724528B2-333B-40A5-A5FD-B5DB2520A826Q34556831-44572C96-AE3D-4A14-B260-A4FC2442EB0DQ34580278-CF793003-66E8-4009-B70A-00268320C4D6Q35638355-7F7E8A21-6630-468D-B369-E62FABD4D77BQ35827683-D2873B98-E467-4205-900B-7F1BD339A2A8Q35848746-CBB00359-D4CC-4E93-ACB4-AA9EB1214B4DQ36299969-6C41D6E0-5A3E-4BEB-A6BF-F7BD7B4D6C37Q36441763-813806BB-8B25-4CE5-A1AA-8C23829EA59AQ36673018-31F89FCB-3AFB-41AC-972C-D0841E100AC7Q36716456-61CD971D-6F93-4FEB-BE22-21D2148BB115Q36740041-BFEE68E7-E52D-4A05-BC53-1FB90E413C1FQ36761358-F8C78419-F6BC-48CC-BF18-102F16AD2B9EQ36792634-0CE67F4D-6E12-47FE-8CCC-0F29C2B205B8Q36904910-CE6165CF-FD26-4ECD-BC2C-82596BCE1366Q37089986-6CD7251D-379D-4579-B0DB-554BD6EC8C1AQ37178937-30AC05B4-0094-45F8-875E-9FE0C880053AQ37219776-2C057569-75F8-4FCF-A615-9C1796AFCB61Q37257464-B799C1E2-6A8C-4E10-9F0D-BCF7C8B2A89BQ37362717-66069FDE-5E18-40DA-AD26-04A6A4663C6FQ37476911-114EB0BE-430D-4E50-93B0-B06A5E93B8CCQ37643458-CF12FFA8-47FF-462D-89CC-30101D749913Q37960192-DD7DA5AB-81CD-4E86-BB07-B12A9527CF93Q38759585-CF91DAF1-AC8A-4827-9FB5-9112351CA88AQ39410727-C428F36D-AD24-47FD-A019-5760D8905294Q40377176-66ACFF4D-EC2B-446C-A4BC-CAEC6CBB77BCQ41686228-31994FA3-F30E-4518-B017-FF539D17EE79Q43062432-0982E149-ECEF-4B84-A727-3D3A49F7FFB1Q43540832-727CEBF0-AE82-43B8-9AC6-9F490D6CD1D8Q46043878-82CA821B-A2D3-43CF-80D1-54DF9B699E38Q46689117-9C5D7FF8-1FAA-4C9B-81FF-9FDC3DFAE2AAQ47372560-4BAD6484-049F-48D0-A6B7-DE8BA4DE0DADQ48193986-7EBA7208-2607-4E34-B33D-75027D2C8B62Q50863884-07878E8B-BB88-42E6-8826-D0C4A00CD430Q58666514-43ACD25E-5758-46F0-939C-10DDA7CF64EDQ58666697-E1075C07-C881-45C3-9592-368E985B1498
P2860
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Differences in outcomes of pat ...... drugs: population based study.
@ast
Differences in outcomes of pat ...... drugs: population based study.
@en
type
label
Differences in outcomes of pat ...... drugs: population based study.
@ast
Differences in outcomes of pat ...... drugs: population based study.
@en
prefLabel
Differences in outcomes of pat ...... drugs: population based study.
@ast
Differences in outcomes of pat ...... drugs: population based study.
@en
P2093
P2860
P1433
P1476
Differences in outcomes of pat ...... drugs: population based study.
@en
P2093
Hugues Richard
Louise Pilote
Marie Hudson
P2860
P356
10.1136/BMJ.330.7504.1370
P407
P577
2005-06-01T00:00:00Z